Harmony Biosciences Holdings, Inc. $HRMY Shares Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets increased its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 32.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 525,145 shares of the company’s stock after acquiring an additional 130,001 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.91% of Harmony Biosciences worth $19,651,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of HRMY. Amundi grew its position in Harmony Biosciences by 115.6% in the 1st quarter. Amundi now owns 39,668 shares of the company’s stock worth $1,229,000 after purchasing an additional 21,266 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Harmony Biosciences by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,651 shares of the company’s stock valued at $752,000 after acquiring an additional 984 shares in the last quarter. Empowered Funds LLC acquired a new position in Harmony Biosciences in the 1st quarter valued at approximately $2,330,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Harmony Biosciences by 53.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 95,389 shares of the company’s stock valued at $3,166,000 after buying an additional 33,058 shares during the period. Finally, Cetera Investment Advisers increased its stake in Harmony Biosciences by 9.8% in the 2nd quarter. Cetera Investment Advisers now owns 8,404 shares of the company’s stock valued at $266,000 after buying an additional 748 shares during the period. Institutional investors own 86.23% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on HRMY. Wall Street Zen downgraded shares of Harmony Biosciences from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Needham & Company LLC reduced their price objective on shares of Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. UBS Group reduced their price objective on shares of Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Mizuho set a $50.00 price objective on shares of Harmony Biosciences in a research report on Thursday, February 19th. Finally, Bank of America lowered their price objective on shares of Harmony Biosciences from $32.00 to $28.00 and set an “underperform” rating for the company in a research report on Wednesday, February 25th. Four research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $40.89.

Harmony Biosciences Price Performance

NASDAQ:HRMY opened at $32.20 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.58 and a quick ratio of 3.56. The firm’s fifty day moving average price is $30.16 and its two-hundred day moving average price is $33.12. Harmony Biosciences Holdings, Inc. has a one year low of $25.52 and a one year high of $40.87. The company has a market cap of $1.86 billion, a P/E ratio of 12.98, a P/E/G ratio of 0.23 and a beta of 0.96.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.55 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.21). Harmony Biosciences had a net margin of 16.20% and a return on equity of 17.19%. The business had revenue of $215.39 million during the quarter, compared to analyst estimates of $220.84 million. During the same quarter last year, the company posted $0.78 earnings per share. The company’s revenue was up 16.6% on a year-over-year basis. Equities analysts expect that Harmony Biosciences Holdings, Inc. will post 3.2 earnings per share for the current year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.